Olodaterol	NN	Olodaterol NN PennPOS
shows	VBZ	show VBZ PennPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
efficacy	NN	efficacy NN PennPOS
in	IN	in IN PennPOS
in	FW	in fw-la NUPOS
vitro	FW	vitro FW PennPOS
and	CC	and cc NUPOS
in	FW	in fw-la NUPOS
vivo	FW	vivo fw-la NUPOS
models	NNS	model NNS PennPOS
of	IN	of pp-f NUPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

BACKGROUND	NN	background NN PennPOS
AND	CC	and cc NUPOS
PURPOSE	NN	purpose NN PennPOS
:	:	: : NUPOS
Idiopathic	JJ	idiopathic JJ PennPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
(	(	( ( NUPOS
IPF	NN	IPF NN PennPOS
)	)	) ) NUPOS
is	VBZ	be vbz NUPOS
a	DT	a dt NUPOS
fatal	JJ	fatal JJ PennPOS
respiratory	JJ	respiratory JJ PennPOS
disease	NN	disease NN PennPOS
characterized	VBN	characterize VBN PennPOS
by	IN	by IN PennPOS
excessive	JJ	excessive JJ PennPOS
fibroblast	NN	fibroblast NN PennPOS
activation	NN	activation NN PennPOS
ultimately	RB	ultimate av-j NUPOS
leading	VBG	lead VBG PennPOS
to	TO	to p-acp NUPOS
scarring	NN	scarring NN PennPOS
of	IN	of pp-f NUPOS
the	DT	the dt NUPOS
lungs	NNS	lung NNS PennPOS
.	.	. . NUPOS

Although	IN	although cs NUPOS
,	,	, , NUPOS
the	DT	the dt NUPOS
activation	NN	activation NN PennPOS
of	IN	of pp-f NUPOS
b2	NN	b2 NN PennPOS
--	:	-- : NUPOS
adrenoceptors	NNS	adrenoceptor NNS PennPOS
(	(	( ( NUPOS
b2	NN	b2 NN PennPOS
--	:	-- : NUPOS
AR	NN	ar NN PennPOS
)	)	) ) NUPOS
has	VBZ	have vdz NUPOS
been	VBN	be vbn NUPOS
shown	VBN	show VBN PennPOS
to	TO	to p-acp NUPOS
inhibit	VB	inhibit VBP PennPOS
pro-fibrotic	JJ	pro-fibrotic JJ PennPOS
events	NNS	event NNS PennPOS
primarily	RB	primary RB PennPOS
in	IN	in IN PennPOS
cell	NN	cell NN PennPOS
lines	NNS	line NNS PennPOS
,	,	, , NUPOS
the	DT	the dt NUPOS
role	NN	role NN PennPOS
of	IN	of pp-f NUPOS
b2	NN	b2 NN PennPOS
-	:	- : NUPOS
adrenoceptor	NN	adrenoceptor NN PennPOS
agonists	NNS	agonist NNS PennPOS
has	VBZ	have vdz NUPOS
not	RB	not xx NUPOS
yet	RB	yet av NUPOS
been	VBN	be vbn NUPOS
fully	RB	full av-j NUPOS
characterized	VBN	characterize VBN PennPOS
.	.	. . NUPOS

The	DT	the dt NUPOS
aim	NN	aim NN PennPOS
of	IN	of pp-f NUPOS
our	PRP$	our po12 NUPOS
study	NN	study NN PennPOS
was	VBD	be vbd NUPOS
to	TO	to p-acp NUPOS
explore	VB	explore VBP PennPOS
the	DT	the dt NUPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
activity	NN	activity NN PennPOS
of	IN	of pp-f NUPOS
the	DT	the dt NUPOS
long-acting	JJ	long-acting JJ PennPOS
b2	NN	b2 NN PennPOS
-	:	- : NUPOS
adrenoceptor	NN	adrenoceptor NN PennPOS
agonist	NN	agonist NN PennPOS
olodaterol	NN	olodaterol NN PennPOS
in	IN	in IN PennPOS
primary	JJ	primary JJ PennPOS
human	JJ	human JJ PennPOS
lung	NN	lung NN PennPOS
fibroblasts	NNS	fibroblast NNS PennPOS
(	(	( ( NUPOS
HLF	NN	HLF NN PennPOS
)	)	) ) NUPOS
and	CC	and cc NUPOS
in	IN	in IN PennPOS
murine	JJ	murine JJ PennPOS
models	NNS	model NNS PennPOS
of	IN	of pp-f NUPOS
pulmonary	JJ	pulmonary JJ PennPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

EXPERIMENTAL	JJ	experimental JJ PennPOS
APPROACH	NN	approach NN PennPOS
:	:	: : NUPOS
We	PRP	we pns12 NUPOS
assessed	VBD	assess VBD PennPOS
the	DT	the dt NUPOS
activity	NN	activity NN PennPOS
of	IN	of pp-f NUPOS
olodaterol	NN	olodaterol NN PennPOS
to	TO	to p-acp NUPOS
inhibit	VB	inhibit VBP PennPOS
various	JJ	various JJ PennPOS
pro-fibrotic	JJ	pro-fibrotic JJ PennPOS
mechanisms	NNS	mechanism NNS PennPOS
,	,	, , NUPOS
induced	VBN	induce VBN PennPOS
by	IN	by IN PennPOS
different	JJ	different JJ PennPOS
pro-fibrotic	JJ	pro-fibrotic JJ PennPOS
mediators	NNS	mediator NNS PennPOS
,	,	, , NUPOS
in	IN	in IN PennPOS
primary	JJ	primary JJ PennPOS
HLF	NN	HLF NN PennPOS
from	IN	from pp NUPOS
control	NN	control NN PennPOS
donors	NNS	donor NNS PennPOS
and	CC	and cc NUPOS
patients	NNS	patient NNS PennPOS
with	IN	with pp NUPOS
IPF	NN	IPF NN PennPOS
(	(	( ( NUPOS
IPF-LF	NN	IPF-LF NN PennPOS
)	)	) ) NUPOS
.	.	. . NUPOS

The	DT	the dt NUPOS
in	FW	in fw-la NUPOS
vivo	FW	vivo fw-la NUPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
activity	NN	activity NN PennPOS
of	IN	of pp-f NUPOS
olodaterol	NN	olodaterol NN PennPOS
,	,	, , NUPOS
given	VBN	give VBN PennPOS
once	RB	once a-acp NUPOS
daily	RB	daily av-j NUPOS
by	IN	by IN PennPOS
inhalation	NN	inhalation NN PennPOS
in	IN	in IN PennPOS
either	CC	either CC PennPOS
a	DT	a dt NUPOS
preventive	JJ	preventive JJ PennPOS
or	CC	or cc NUPOS
therapeutic	JJ	therapeutic JJ PennPOS
treatment	NN	treatment NN PennPOS
regimen	NN	regimen NN PennPOS
,	,	, , NUPOS
was	VBD	be vbd NUPOS
explored	VBN	explore VBN PennPOS
in	IN	in IN PennPOS
murine	JJ	murine JJ PennPOS
models	NNS	model NNS PennPOS
of	IN	of pp-f NUPOS
lung	NN	lung NN PennPOS
fibrosis	NN	fibrosis NN PennPOS
induced	VBN	induce VBN PennPOS
by	IN	by IN PennPOS
either	CC	either CC PennPOS
bleomycin	NN	bleomycin NN PennPOS
or	CC	or cc NUPOS
the	DT	the dt NUPOS
overexpression	NN	overexpression NN PennPOS
of	IN	of pp-f NUPOS
TGF-b1	NN	TGF-b1 NN PennPOS
.	.	. . NUPOS

KEY	JJ	key JJ PennPOS
RESULTS	NNS	result NNS PennPOS
:	:	: : NUPOS
In	IN	in IN PennPOS
both	DT	both d NUPOS
HLF	NN	HLF NN PennPOS
and	CC	and cc NUPOS
IPF-LF	NN	IPF-LF NN PennPOS
,	,	, , NUPOS
olodaterol	NN	olodaterol NN PennPOS
attenuated	VBD	attenuate VBD PennPOS
TGF-b-induced	JJ	tgf-b-induced JJ PennPOS
expression	NN	expression NN PennPOS
of	IN	of pp-f NUPOS
a-smooth-muscle-actin	NN	a-smooth-muscle-actin NN PennPOS
,	,	, , NUPOS
fibronectin	NN	fibronectin NN PennPOS
and	CC	and cc NUPOS
endothelin-1	NN	endothelin-1 NN PennPOS
(	(	( ( NUPOS
ET-1	NN	ET-1 NN PennPOS
)	)	) ) NUPOS
,	,	, , NUPOS
FGF	NN	FGF NN PennPOS
-	:	- : NUPOS
and	CC	and cc NUPOS
PDGF-induced	JJ	pdgf-induced JJ PennPOS
motility	NN	motility NN PennPOS
and	CC	and cc NUPOS
proliferation	NN	proliferation NN PennPOS
and	CC	and cc NUPOS
TGF-b/ET	NN	TGF-b/ET NN PennPOS
-1-induced	JJ	-1-induced JJ PennPOS
contraction	NN	contraction NN PennPOS
.	.	. . NUPOS

In	FW	in fw-la NUPOS
vivo	FW	vivo fw-la NUPOS
olodaterol	NN	olodaterol NN PennPOS
significantly	RB	significant av-j NUPOS
attenuated	VBD	attenuate VBD PennPOS
the	DT	the dt NUPOS
bleomycin-induced	JJ	bleomycin-induced JJ PennPOS
increase	NN	increase NN PennPOS
in	IN	in IN PennPOS
lung	NN	lung NN PennPOS
weight	NN	weight NN PennPOS
,	,	, , NUPOS
reduced	VBD	reduce VBD PennPOS
bronchoalveolar	JJ	bronchoalveolar JJ PennPOS
lavage	NN	lavage NN PennPOS
cell	NN	cell NN PennPOS
counts	NNS	count NNS PennPOS
and	CC	and cc NUPOS
inhibited	VBD	inhibit VBD PennPOS
release	NN	release NN PennPOS
of	IN	of pp-f NUPOS
pro-fibrotic	JJ	pro-fibrotic JJ PennPOS
mediators	NNS	mediator NNS PennPOS
(	(	( ( NUPOS
TGF	NN	tgf NN PennPOS
-	:	- : NUPOS
,	,	, , NUPOS
MMP-9	NN	MMP-9 NN PennPOS
and	CC	and cc NUPOS
tissue	NN	tissue NN PennPOS
inhibitor	NN	inhibitor NN PennPOS
of	IN	of pp-f NUPOS
metalloproteinase-1	NN	metalloproteinase-1 NN PennPOS
)	)	) ) NUPOS
.	.	. . NUPOS

Forced	VBN	force VBN PennPOS
vital	JJ	vital JJ PennPOS
capacity	NN	capacity NN PennPOS
was	VBD	be vbd NUPOS
increased	VBN	increase VBN PennPOS
only	RB	only av-j NUPOS
with	IN	with pp NUPOS
the	DT	the dt NUPOS
preventive	JJ	preventive JJ PennPOS
treatment	NN	treatment NN PennPOS
regimen	NN	regimen NN PennPOS
.	.	. . NUPOS

In	IN	in IN PennPOS
the	DT	the dt NUPOS
TGF-b-overexpressing	JJ	tgf-b-overexpressing JJ PennPOS
model	NN	model NN PennPOS
,	,	, , NUPOS
olodaterol	NN	olodaterol NN PennPOS
additionally	RB	additional RB PennPOS
reduced	VBD	reduce VBD PennPOS
the	DT	the dt NUPOS
Col3A1	NN	Col3A1 NN PennPOS
mRNA	NN	mRNA NN PennPOS
expression	NN	expression NN PennPOS
.	.	. . NUPOS

CONCLUSION	NN	conclusion NN PennPOS
AND	CC	and cc NUPOS
IMPLICATIONS	NNS	implication NNS PennPOS
:	:	: : NUPOS
Olodaterol	NN	Olodaterol NN PennPOS
showed	VBD	show VBN PennPOS
anti-fibrotic	JJ	anti-fibrotic JJ PennPOS
properties	NNS	property NNS PennPOS
in	IN	in IN PennPOS
primary	JJ	primary JJ PennPOS
HLF	NN	HLF NN PennPOS
from	IN	from pp NUPOS
control	NN	control NN PennPOS
and	CC	and cc NUPOS
IPF	NN	IPF NN PennPOS
patients	NNS	patient NNS PennPOS
and	CC	and cc NUPOS
in	IN	in IN PennPOS
murine	JJ	murine JJ PennPOS
models	NNS	model NNS PennPOS
of	IN	of pp-f NUPOS
lung	NN	lung NN PennPOS
fibrosis	NN	fibrosis NN PennPOS
.	.	. . NUPOS

